Introduction & Contents

Introduction

Welcome to the new TIDES eBook Series from Informa Connect Life Sciences. Each edition investigates one area of oligonucleotide and peptide therapeutics. In this first edition, we explore ways in which chemistry, manufacturing and controls (CMC) can be optimized.

The task of developing oligonucleotide- and peptide-based therapeutic products faces unique challenges, making it difficult to meet regulatory requirements and scale production for commercialization. Due to their size and molecular complexity, peptides and oligos require special considerations along the way. Without innovation, CMC processes are likely to suffer additional strain from the ever-increasing demand in the market.

In the next pages, we explore CMC challenges in depth and identify the opportunities for optimization which lie ahead in technology, partnering strategies and technical approaches adopted by leaders in the industry.

Jump to any article using the contents on the following page, or at any time using the Contents menu in the top left. There you can also download this eBook as a PDF.

Table of Contents

1. Case study: Generating a SARS-CoV-2 Epitope Library, Conducted by Gyros Protein Technologies

The synthesis by Gyros Protein Technologies of the 24 SARS-CoV-2 peptides with therapeutic potential published by Grifoni and colleagues (7) represents a real-world example of synthetic challenges brought by a diverse range of sequences.

2. CMC Approaches to Accelerate Peptide, Oligonucleotides and mRNA therapeutics Development

Peptides represent a unique class of pharmaceutical compounds, molecularly poised between small molecules and proteins, yet biochemically and therapeutically different from both.

3. Partnering in the Oligonucleotide and Peptide Therapeutics Industry

This whitepaper looks at the challenges and opportunities facing the peptide and oligonucleotide therapeutics industry in partnering, business development and commercialization strategies, using a
number of case studies.

4. How AI Could Revolutionize Chemistry

An interview with John Lopez, Process Development Chemist at Novartis, who explores how Artificial Intelligence can revolutionize chemistry to make it a data driven field.

5. Q&A With Ajinomoto Biopharma Services: Partnering with the Right CDMO

The challenges to a CDMO partner is to cost-effectively, quickly and easily scale up your oligonucleotide from research to commercial quantities, as well as having the facilities in place to manage commercial scale quantities.